FY2025 EPS Estimates for Certara Reduced by Leerink Partnrs

Certara, Inc. (NASDAQ:CERT) – Equities researchers at Leerink Partnrs cut their FY2025 earnings estimates for Certara in a research note issued to investors on Sunday, November 17th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $0.32 per share for the year, down from their prior estimate of $0.33. The consensus estimate for Certara’s current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara’s FY2027 earnings at $0.40 EPS.

A number of other equities research analysts have also recently weighed in on the company. Robert W. Baird dropped their price target on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, September 27th. Finally, Barclays decreased their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $15.92.

Certara Price Performance

NASDAQ:CERT opened at $9.55 on Tuesday. Certara has a 12-month low of $9.55 and a 12-month high of $19.87. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -47.75, a P/E/G ratio of 5.04 and a beta of 1.51. The stock’s 50 day moving average price is $10.82 and its two-hundred day moving average price is $13.30. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same period in the previous year, the business earned $0.06 EPS. Certara’s revenue for the quarter was up 10.7% compared to the same quarter last year.

Insider Buying and Selling

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 33.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by insiders.

Institutional Trading of Certara

Several large investors have recently made changes to their positions in CERT. Blue Trust Inc. acquired a new stake in shares of Certara in the 2nd quarter valued at $26,000. Innealta Capital LLC acquired a new stake in shares of Certara in the 2nd quarter valued at approximately $36,000. KBC Group NV lifted its stake in Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after purchasing an additional 1,584 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Certara in the second quarter valued at approximately $152,000. Finally, Algert Global LLC acquired a new position in Certara in the 2nd quarter worth about $156,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.